{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-144217","form_type":"8-K","ticker":"BNTC","cik":"0001808898","company_name":"Benitec Biopharma Inc.","filed_at":"2023-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.707314+00:00","generated_at":"2026-06-15T01:26:23.611672+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Benitec Q3 net loss $4.4M; 9 subjects enrolled in OPMD study; on track for BB-301 dosing in 2H2023","bullets":["Net loss of $4.4M ($0.16/shr) in Q3 2023 vs $3.3M ($0.40/shr) in Q3 2022; cash $6.6M at Mar 31, 2023.","9 subjects enrolled in OPMD Natural History Study in the U.S.; pace supports BB-301 dosing and interim data disclosure in 2H2023.","R&D expenses $3.17M vs $2.17M YoY, driven by GMP manufacturing and Natural History Study; operating loss $4.4M.","Expects FDA IND response for BB-301 in Q2 2023; Canadian site activation pending REB approval.","CEO Jerel Banks to present at OPMD International Conference in Tel Aviv on May 16, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-144217","json":"https://secwatch.observer/filing/0001193125-23-144217.json","markdown":"https://secwatch.observer/filing/0001193125-23-144217.md","text":"https://secwatch.observer/filing/0001193125-23-144217.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1808898/000119312523144217/0001193125-23-144217-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1808898/000119312523144217/d480708d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T01:26:23.611672+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bc879bed8c4f949ebc177890a9bd87e60ab20b31","claim":"Benitec Biopharma Inc. reported financial results for Third Fiscal Quarter ended March 31, 2023.","evidence_excerpt":"On May 15, 2023 Benitec Biopharma Inc. (the “Company”) issued a press release announcing the Company’s financial results for its fiscal quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1808898/000119312523144217/0001193125-23-144217-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Third Fiscal Quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}